Clinical Trials Browser

C188-9 compound × Head & Neck × Clear all

NCT05668949 2025-12-17

Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 1/2 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05845307 2025-12-08

Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck

Phase EARLY_PHASE1 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03195699 2025-03-21

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Phase 1 Completed

64 enrolled

BreastDermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Neoplasms, Colorectal Neoplasms